Mga Batayang Estadistika
| LEI | 549300NK4AB8OUEX1F54 |
| CIK | 1641634 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to GenSight Biologics S.A.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| April 14, 2016 |
RW April 14, 2016 VIA EDGAR AND COURIER Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N. |
|
| November 3, 2015 |
Form 8-A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A For Registration of Certain Classes of Securities Pursuant to Section 12(b) or 12(g) of the Securities Exchange Act of 1934 GENSIGHT BIOLOGICS S.A. (Exact name of registrant as specified in its charter) France Not Applicable (State of Incorporation or organization) (I.R.S. Employer Identification No.) 74, rue |
|
| November 3, 2015 |
As Filed with the Securities and Exchange Commission on November 3, 2015 F-1/A Amendment 6 Table of Contents As Filed with the Securities and Exchange Commission on November 3, 2015 Registration No. |
|
| October 27, 2015 |
As Filed with the Securities and Exchange Commission on October 27, 2015 F-1/A Amendment No.5 Table of Contents As Filed with the Securities and Exchange Commission on October 27, 2015 Registration No. 333-205539 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 5 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GENSIGHT BIOLOGICS S.A. (Exact name of registrant as specified in its charter) France 2836 Not applicabl |
|
| October 26, 2015 |
=============================================================== GENSIGHT BIOLOGICS S. |
|
| October 26, 2015 |
Writer’s Direct Dial EXHIBIT 4 Emmet, Marvin & Martin, LLP Counsellors at Law 120 Broadway New York, New York 10271 (212) 238-3000 (212) 653-1760 Fax: (212) 238-3100 Fax: (212) 653-1730 http://www. |
|
| October 26, 2015 |
As filed with the Securities and Exchange Commission on October 26, 2015 F-6 1 gena425849f6.htm FORM F-6 As filed with the Securities and Exchange Commission on October 26, 2015 Registration No. 333- SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-6 REGISTRATION STATEMENT under THE SECURITIES ACT OF 1933 For American Depositary Shares of GENSIGHT BIOLOGICS S.A. (Exact name of issuer of deposited securities as specified in its charter) N/A (Translation |
|
| October 6, 2015 |
As Filed with the Securities and Exchange Commission on October 6, 2015 F-1/A 1 d921461df1a.htm FORM F-1/A4 Table of Contents As Filed with the Securities and Exchange Commission on October 6, 2015 Registration No. 333-205539 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 4 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GENSIGHT BIOLOGICS S.A. (Exact name of registrant as specified in its charter) France 2836 |
|
| October 6, 2015 |
EX-3.2 3 d921461dex32.htm EX-3.2 Exhibit 3.2 Uncertified translation for information purposes only GenSight Biologics A French company (société anonyme) with share capital of €[●] 74 rue du Faubourg Saint Antoine 75012 Paris Paris Trade and Companies Register No. 751 164 757 BYLAWS UPDATED ON [●] 2015 SECTION I FORM - PURPOSE - NAME - HEAD OFFICE - TERM Article 1 - FORM The company is a société an |
|
| October 6, 2015 |
Exhibit 1.1 GENSIGHT BIOLOGICS S.A. (a société anonyme incorporated under the laws of France) [●] American Depositary Shares, Each Representing [●] Ordinary Share[s] (nominal value €[●] per share) UNDERWRITING AGREEMENT Dated: [●], 2015 GENSIGHT BIOLOGICS S.A. (a société anonyme incorporated under the laws of France) [●] American Depositary Shares, Each Representing [●] Ordinary Share[s] (nominal |
|
| October 6, 2015 |
EX-4.1 4 d921461dex41.htm EX-4.1 Exhibit 4.1 GENSIGHT BIOLOGICS S.A. AND THE BANK OF NEW YORK MELLON As Depositary AND OWNERS AND HOLDERS OF AMERICAN DEPOSITARY SHARES Deposit Agreement , 2015 TABLE OF CONTENTS ARTICLE 1. DEFINITIONS 1 SECTION 1.1. American Depositary Shares. 1 SECTION 1.2. Commission. 2 SECTION 1.3. Company. 2 SECTION 1.4. Custodian. 2 SECTION 1.5. Delisting Event. 2 SECTION 1.6. |
|
| September 10, 2015 |
Exhibit 10.9 [**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. COOPERATION AGREEMENT BY AND BETWEEN Pierre and Marie Curie University (Paris 6), a French public, scientific, cultural and professional establishment located at 4 Place Jussieu, 75252 Paris Cedex 05 Hereinafter referred to as UPMC Represented by Professor Jean |
|
| September 10, 2015 |
MASTER Funding for the Projet Structurant des Pôles de Compétitivité “SIGHT AGAIN” Exhibit 10.7 [**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. MASTER AGREEMENT Funding for the Projet Structurant des Pôles de Compétitivité “SIGHT AGAIN” BETWEEN THE UNDERSIGNED Bpifrance Financement A French Société Anonyme, with share capital of €759,916,144, registered in the Créteil Trade and Companies’ Register under |
|
| September 10, 2015 |
CONSORTIUM AGREEMENT SIGHT AGAIN Projet de R&D Structurant Pour La Compétitivité Exhibit 10.6 [**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. CONSORTIUM AGREEMENT SIGHT AGAIN Projet de R&D Structurant Pour La Compétitivité BETWEEN: GenSight Biologics, a French public limited company (“Société Anonyme”) with share capital of €218,867.23, whose head office is at 89 Rue du Faubourg St Antoine, 75011 Pari |
|
| September 10, 2015 |
As Filed with the Securities and Exchange Commission on September 10, 2015 Table of Contents As Filed with the Securities and Exchange Commission on September 10, 2015 Registration No. |
|
| September 10, 2015 |
SPECIFIC RESEARCH COOPERATION AGREEMENT Exhibit 10.13 [**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. SPECIFIC RESEARCH COOPERATION AGREEMENT BY AND BETWEEN Pierre et Marie Curie University (Paris 6), a French public, scientific, cultural and professional establishment located at 4 Place Jussieu, 75252 Paris Cedex 05 Hereinafter referred to as UPMC Represented |
|
| September 10, 2015 |
LICENSE for the USE of SCIENTIFIC DATA Exhibit 10.18 [**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. LICENSE for the USE of SCIENTIFIC DATA THIS EXCLUSIVE LICENSE Agreement is made the 2 day of December 2013, BETWEEN Association Française contre les Myopathies (AFM), Non Profit Association governed by the French law of July 1, 1901, reconnue d’utilité publique |
|
| September 10, 2015 |
SPECIFIC RESEARCH COOPERATION AGREEMENT UPMC REF. NO.: C15/0855 GENSIGHT REF. NO.: XXXX Exhibit 10.15 [**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. SPECIFIC RESEARCH COOPERATION AGREEMENT UPMC REF. NO.: C15/0855 GENSIGHT REF. NO.: XXXX 1. BY AND BETWEEN Pierre et Marie Curie University (Paris 6), a French public, scientific, cultural and professional establishment located at 4 Place Jussieu, 75252 Paris Ce |
|
| September 10, 2015 |
SPECIFIC RESEARCH COOPERATION AGREEMENT Exhibit 10.14 [**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. SPECIFIC RESEARCH COOPERATION AGREEMENT BY AND BETWEEN Pierre et Marie Curie University (Paris 6), a French public, scientific, cultural and professional establishment located at 4 Place Jussieu, 75252 Paris Cedex 05 Hereinafter referred to as UPMC Represented |
|
| September 10, 2015 |
Exhibit 3.1 Uncertified translation for information purposes only GenSight Biologics A French company (société anonyme) with share capital of €340,228.05 74 rue du Faubourg Saint Antoine 75012 Paris Paris Trade and Companies Register No. 751 164 757 BYLAWS UPDATED BY THE GENERAL ASSEMBLY MEETING ON AUGUST 17, 2015 GenSight Biologics A French société anonyme (Corporation) with a share capital of €3 |
|
| September 10, 2015 |
AMENDMENT No. 3 TO THE COOPERATION AGREEMENT Exhibit 10.12 [**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. AMENDMENT No. 3 TO THE COOPERATION AGREEMENT By and between Pierre et Marie Curie University (Paris 6) a French public, scientific, cultural and professional establishment SIRET No.: 19751722000012 - APE Code: 8452Z 4 Place Jussieu, 75252 Paris Cedex 05 Represe |
|
| September 10, 2015 |
EX-10.17 13 d921461dex1017.htm EXHIBIT 10.17 Exhibit 10.17 [**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. LICENSE AGREEMENT N° 05064A10 This License Agreement (the “Agreement”) is made as of its last date of signature by all signatories (the “Effective Date”) by and between: Inserm Transfert SA, a limited company (sociét |
|
| September 10, 2015 |
ADDENDUM 1.1 No. 012174-1NOHL-01.1 TO THE PARTNERSHIP AGREEMENT No. 012174-1NOHL-OO Exhibit 10.3 [**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. ADDENDUM 1.1 No. 012174-1NOHL-01.1 TO THE PARTNERSHIP AGREEMENT No. 012174-1NOHL-OO This Project Addendum 1.1 (the “Project Addendum 1.1”) is made and entered into as of 1 January 2014 (the “Project Addendum 1.1 Effective Date”), by and between GenSight Biologic |
|
| September 10, 2015 |
RESEARCH COLLABORATION AGREEMENT Exhibit 10.4 [**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. RESEARCH COLLABORATION AGREEMENT This Research Collaboration Agreement (the “Agreement”) having an Effective Date of March 1st, 2014, is made between the Friedrich Miescher Institute for Biomedical Research (“FMI”) located at Maulbeerstrasse 66, 4058 Basel, Swit |
|
| September 10, 2015 |
PARTNERSHIP AGREEMENT No. 012174-1NOHL-00 Exhibit 10.1 [**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. PARTNERSHIP AGREEMENT No. 012174-1NOHL-00 This partnership agreement (the “Partnership Agreement”) is made and entered into as of February 1, 2013 (the “Effective Date”), by and between GenSight Biologics SA, a corporation organized under the laws of France, reg |
|
| August 10, 2015 |
Exhibit 10.20 Summary of BSPCE Plan Share warrants for founders, or BSPCEs, entitle a holder to exercise the warrant for the underlying vested shares at an exercise price per share determined by our board of directors and at least equal to the fair market value of an ordinary share on the date of grant. Share warrants for founders may only be issued by growth companies meeting certain criteria. Th |
|
| August 10, 2015 |
As Filed with the Securities and Exchange Commission on August 10, 2015 Form F-1/A Table of Contents As Filed with the Securities and Exchange Commission on August 10, 2015 Registration No. |
|
| August 10, 2015 |
Exhibit 3.1 Uncertified translation for information purposes only GenSight Biologics A French company (soci?t? anonyme) with share capital of ?340,228.01 74 rue du Faubourg Saint Antoine 75012 Paris Paris Trade and Companies Register No. 751 164 757 BYLAWS UPDATED BY THE BOARD OF DIRECTORS MEETING ON JULY 7, 2015 GenSight Biologics A French soci?t? anonyme (Corporation) with a share capital of ?34 |
|
| August 10, 2015 |
Exhibit 10.22 REGISTRATION RIGHTS AGREEMENT among GENSIGHT BIOLOGICS S.A. and THE SHAREHOLDERS PARTY HERETO TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS Section 1.01 . Definitions 1 Section 1.02 . Other Definitional and Interpretative Provisions 4 ARTICLE 2 REGISTRATION RIGHTS Section 2.01 . Demand Registration 5 Section 2.02 . Piggyback Registration 7 Section 2.03 . Shelf Registration 9 Section 2 |
|
| August 10, 2015 |
Exhibit 10.19 Summary of BSA Plan Share warrants, or BSAs, entitle a holder to exercise the warrant for the underlying vested shares at an exercise price per share determined by our board of directors and at least equal to the fair market value of an ordinary share on the date of grant. In addition to any exercise price payable by a holder upon the exercise of any share warrant, share warrants nee |
|
| July 10, 2015 |
F-1/A As Filed with the Securities and Exchange Commission on July 10, 2015 Registration No. |
|
| July 10, 2015 |
Exhibit 10.21 Exhibit 10.21 [**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Biopharma Services Agreement Manufacturing of cGMP batches of GS010 rAAV2/2-ND4 Date : Thursday, June 25, 2015 STATUS - Budget indication (non-binding) ? - Working document (non-binding) ? - Final version for signature x Biopharma Services Agreeme |
|
| July 7, 2015 |
PARTNERSHIP AGREEMENT No. 012174-1NOHL-00 Exhibit 10.1 [**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. PARTNERSHIP AGREEMENT No. 012174-1NOHL-00 This partnership agreement (the ?Partnership Agreement?) is made and entered into as of February 1, 2013 (the ?Effective Date?), by and between GenSight Biologics SA, a corporation organized under the laws of France, reg |
|
| July 7, 2015 |
As Filed with the Securities and Exchange Commission on July 7, 2015 F-1 Table of Contents As Filed with the Securities and Exchange Commission on July 7, 2015 Registration No. |
|
| July 7, 2015 |
QUALITY AGREEMENT No. 014180-1NOHL-00 Exhibit 10.5 [**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. QUALITY AGREEMENT No. 014180-1NOHL-00 This quality agreement (the ?Quality Agreement?) is made and entered into as of 10th June 2014, by and between GENETHON, a non-profit organization organized under the laws of France (SIRET: 40218752000018), with its principa |
|
| July 7, 2015 |
ADDENDUM 1.1 No. 012174-1NOHL-01.1 TO THE PARTNERSHIP AGREEMENT No. 012174-1NOHL-OO Exhibit 10.3 Exhibit 10.3 [**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. ADDENDUM 1.1 No. 012174-1NOHL-01.1 TO THE PARTNERSHIP AGREEMENT No. 012174-1NOHL-OO This Project Addendum 1.1 (the “Project Addendum 1.1”) is made and entered into as of 1 January 2014 (the “Project Addendum 1.1 Effective Date”), by and between GenS |
|
| July 7, 2015 |
SPECIFIC RESEARCH COOPERATION AGREEMENT Exhibit 10.14 Exhibit 10.14 [**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. SPECIFIC RESEARCH COOPERATION AGREEMENT BY AND BETWEEN Pierre et Marie Curie University (Paris 6), a French public, scientific, cultural and professional establishment located at 4 Place Jussieu, 75252 Paris Cedex 05 Hereinafter referred to as UPM |
|
| July 7, 2015 |
Exhibit 10.8 [**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. REFUNDABLE ADVANCE BENEFICIARY AGREEMENT (FINANCIAL AID AGREEMENT) Funding for Business Cluster Development Project “SIGHT AGAIN” BETWEEN THE UNDERSIGNED Bpifrance Financement A French public limited company (“Société Anonyme”) with share capital of €759,916,144 |
|
| July 7, 2015 |
ADDENDUM 1 No. 012174-1NOHL-01 TO THE PARTNERSHIP AGREEMENT No. 012174-1NOHL-OO Exhibit 10.2 Exhibit 10.2 [**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. ADDENDUM 1 No. 012174-1NOHL-01 TO THE PARTNERSHIP AGREEMENT No. 012174-1NOHL-OO This Project Addendum 1 (the “Project Addendum 1”) is made and entered into as of 2 April 2013 (the “Project Addendum 1 Effective Date”), by and between GenSight Biologi |
|
| July 7, 2015 |
RESEARCH COLLABORATION AGREEMENT Exhibit 10.4 [**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. RESEARCH COLLABORATION AGREEMENT This Research Collaboration Agreement (the ?Agreement?) having an Effective Date of March 1st, 2014, is made between the Friedrich Miescher Institute for Biomedical Research (?FMI?) located at Maulbeerstrasse 66, 4058 Basel, Swit |
|
| July 7, 2015 |
Exhibit 10.16 Exhibit 10.16 [**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. LICENSE AGREEMENT This LICENSE AGREEMENT (this “Agreement”) is entered into effective as of February 23, 2014 (the “Effective Date”) between GENSIGHT BIOLOGICS, S.A., a French corporation with offices at 89, rue du Faubourg St Antoine 75011 Paris |
|
| July 7, 2015 |
SPECIFIC RESEARCH COOPERATION AGREEMENT Exhibit 10.13 [**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. SPECIFIC RESEARCH COOPERATION AGREEMENT BY AND BETWEEN Pierre et Marie Curie University (Paris 6), a French public, scientific, cultural and professional establishment located at 4 Place Jussieu, 75252 Paris Cedex 05 Hereinafter referred to as UPMC Represented |
|
| July 7, 2015 |
AMENDMENT No. 3 TO THE COOPERATION AGREEMENT Exhibit 10.12 [**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. AMENDMENT No. 3 TO THE COOPERATION AGREEMENT By and between Pierre et Marie Curie University (Paris 6) a French public, scientific, cultural and professional establishment SIRET No.: 19751722000012 - APE Code: 8452Z 4 Place Jussieu, 75252 Paris Cedex 05 Represe |
|
| July 7, 2015 |
Exhibit 10.9 Exhibit 10.9 [**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. COOPERATION AGREEMENT BY AND BETWEEN Pierre and Marie Curie University (Paris 6), a French public, scientific, cultural and professional establishment located at 4 Place Jussieu, 75252 Paris Cedex 05 Hereinafter referred to as UPMC Represented by Pr |
|
| July 7, 2015 |
CONSORTIUM AGREEMENT SIGHT AGAIN Projet de R&D Structurant Pour La Comp?tetivit? Exhibit 10.6 Exhibit 10.6 [**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. CONSORTIUM AGREEMENT SIGHT AGAIN Projet de R&D Structurant Pour La Compétetivité BETWEEN: GenSight Biologics, a French public limited company (“Société Anonyme”) with share capital of €218,867.23, whose head office is at 89 Rue du Faubourg St Antoin |
|
| July 7, 2015 |
Exhibit 10.19 Exhibit 10.19 Summary of BSA Plan Share warrants, or BSAs, entitle a holder to exercise the warrant for the underlying vested shares at an exercise price per share determined by our board of directors and equal to the market value of an ordinary share on the date of grant. In addition to any exercise price payable by a holder upon the exercise of any share warrant, share warrants nee |
|
| July 7, 2015 |
LICENSE for the USE of SCIENTIFIC DATA Exhibit 10.18 [**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. LICENSE for the USE of SCIENTIFIC DATA THIS EXCLUSIVE LICENSE Agreement is made the 2 day of December 2013, BETWEEN Association Française contre les Myopathies (AFM), Non Profit Association governed by the French law of July 1, 1901, reconnue d’utilité publique |
|
| July 7, 2015 |
Exhibit 10.17 [**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. LICENSE AGREEMENT N° 05064A10 This License Agreement (the “Agreement”) is made as of its last date of signature by all signatories (the “Effective Date”) by and between: Inserm Transfert SA, a limited company (société anonyme à directoire et conseil de surveill |
|
| July 7, 2015 |
Exhibit 10.20 Summary of BSPCE Plan Share warrants for founders, or BSPCEs, entitle a holder to exercise the warrant for the underlying vested shares at an exercise price per share determined by our board of directors and equal to the market value of an ordinary share on the date of grant. Share warrants for founders may only be issued by growth companies meeting certain criteria. There is no lega |
|
| July 7, 2015 |
MASTER Funding for the Projet Structurant des P?les de Comp?titivit? ?SIGHT AGAIN? Exhibit 10.7 Exhibit 10.7 [**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. MASTER AGREEMENT Funding for the Projet Structurant des Pôles de Compétitivité “SIGHT AGAIN” BETWEEN THE UNDERSIGNED Bpifrance Financement A French Société Anonyme, with share capital of €759,916,144, registered in the Créteil Trade and Companies’ R |
|
| July 7, 2015 |
2nd AMENDMENT TO THE COOPERATION AGREEMENT Exhibit 10.11 Exhibit 10.11 2nd AMENDMENT TO THE COOPERATION AGREEMENT BY AND BETWEEN Pierre and Marie Curie University (Paris 6), a French public, scientific, cultural and professional establishment located at 4 Place Jussieu, 75252 Paris Cedex 05 Hereinafter referred to as UPMC Represented by Professor Jean CHAMBAZ, President, And Institut National de la Santé et de la Recherche Médicale (French |
|
| July 7, 2015 |
1st AMENDMENT TO THE COOPERATION Exhibit 10.10 Exhibit 10.10 1st AMENDMENT TO THE COOPERATION AGREEMENT BY AND BETWEEN Pierre and Marie Curie University (Paris 6), a French public, scientific, cultural and professional establishment located at 4 Place Jussieu, 75252 Paris Cedex 05 Hereinafter referred to as UPMC Represented by Professor Jean CHAMBAZ, President, And Institut National de la Santé et de la Recherche Médicale (French |
|
| July 7, 2015 |
SPECIFIC RESEARCH COOPERATION AGREEMENT UPMC REF. NO.: C15/0855 GENSIGHT REF. NO.: XXXX Exhibit 10.15 Exhibit 10.15 [**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. SPECIFIC RESEARCH COOPERATION AGREEMENT UPMC REF. NO.: C15/0855 GENSIGHT REF. NO.: XXXX 1. BY AND BETWEEN Pierre et Marie Curie University (Paris 6), a French public, scientific, cultural and professional establishment located at 4 Place Jussieu, |
|
| July 7, 2015 |
Exhibit 3.1 Exhibit 3.1 Uncertified translation for information purposes only GenSight Biologics A French company (société anonyme) with share capital of €340,228.01 74 rue du Faubourg Saint Antoine 75012 Paris Paris Trade and Companies Register No. 751 164 757 BYLAWS UPDATED BY THE EXTRAORDINARY GENERAL MEETING ON JUNE 29, 2015 GenSight Biologics A French société anonyme (Corporation) with a shar |
|
| June 18, 2015 |
LICENSE for the USE of SCIENTIFIC DATA EX-10.18 Exhibit 10.18 [**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. LICENSE for the USE of SCIENTIFIC DATA THIS EXCLUSIVE LICENSE Agreement is made the 2 day of December 2013, BETWEEN Association Française contre les Myopathies (AFM), Non Profit Association governed by the French law of July 1, 1901, reconnue d’utilité |
|
| June 18, 2015 |
DRS/A 1 filename1.htm Table of Contents As confidentially submitted to the Securities and Exchange Commission on June 18, 2015 As Amendment No. 1 to the confidential submission. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GENSIGHT BIOLOGICS S.A. (Exact name of registrant as specified |
|
| June 18, 2015 |
RESEARCH COLLABORATION AGREEMENT Exhibit 10.4 [**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. RESEARCH COLLABORATION AGREEMENT This Research Collaboration Agreement (the “Agreement”) having an Effective Date of March 1st, 2014, is made between the Friedrich Miescher Institute for Biomedical Research (“FMI”) located at Maulbeerstrasse 66, 4058 Basel, Swit |
|
| June 18, 2015 |
EX-10.17 Exhibit 10.17 [**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. LICENSE AGREEMENT N° 05064A10 This License Agreement (the “Agreement”) is made as of its last date of signature by all signatories (the “Effective Date”) by and between: Inserm Transfert SA, a limited company (société anonyme à directoire et conseil de |
|
| June 18, 2015 |
EX-10.16 Exhibit 10.16 [**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. LICENSE AGREEMENT This LICENSE AGREEMENT (this “Agreement”) is entered into effective as of February 23, 2014 (the “Effective Date”) between GENSIGHT BIOLOGICS, S.A., a French corporation with offices at 89, rue du Faubourg St Antoine 75011 Paris (“Gen |
|
| June 18, 2015 |
PARTNERSHIP AGREEMENT No. 012174-1NOHL-00 Exhibit 10.1 [**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. PARTNERSHIP AGREEMENT No. 012174-1NOHL-00 This partnership agreement (the ?Partnership Agreement?) is made and entered into as of February 1, 2013 (the ?Effective Date?), by and between GenSight Biologics SA, a corporation organized under the laws of France, reg |
|
| June 18, 2015 |
QUALITY AGREEMENT No. 014180-1NOHL-00 EX-10.5 Exhibit 10.5 [**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. QUALITY AGREEMENT No. 014180-1NOHL-00 This quality agreement (the “Quality Agreement”) is made and entered into as of 10th June 2014, by and between GENETHON, a non-profit organization organized under the laws of France (SIRET: 40218752000018), with its |
|
| June 18, 2015 |
ADDENDUM 1.1 No. 012174-1NOHL-01.1 TO THE PARTNERSHIP AGREEMENT No. 012174-1NOHL-OO EX-10.3 Exhibit 10.3 [**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. ADDENDUM 1.1 No. 012174-1NOHL-01.1 TO THE PARTNERSHIP AGREEMENT No. 012174-1NOHL-OO This Project Addendum 1.1 (the “Project Addendum 1.1”) is made and entered into as of 1 January 2014 (the “Project Addendum 1.1 Effective Date”), by and between GenSight |
|
| June 18, 2015 |
ADDENDUM 1 No. 012174-1NOHL-01 TO THE PARTNERSHIP AGREEMENT No. 012174-1NOHL-OO EX-10.2 Exhibit 10.2 [**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. ADDENDUM 1 No. 012174-1NOHL-01 TO THE PARTNERSHIP AGREEMENT No. 012174-1NOHL-OO This Project Addendum 1 (the “Project Addendum 1”) is made and entered into as of 2 April 2013 (the “Project Addendum 1 Effective Date”), by and between GenSight Biologics SA |
|
| May 13, 2015 |
DRS Table of Contents As confidentially submitted to the Securities and Exchange Commission on May 13, 2015 Registration No. |
